Editas Medicine (EDIT) Share-based Compensation (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Share-based Compensation data on file, last reported at $766000.0 in Q1 2025.

• On a quarterly basis, Share-based Compensation fell 89.9% year-over-year to $766000.0 in Q1 2025; TTM through Sep 2025 was -$15.2 million, a 366.01% decrease from a year earlier, with the FY2024 full-year figure at $1.5 million, down 46.26% from the prior year.
• Share-based Compensation for Q1 2025 stood at $766000.0, up from -$15.9 million in the prior quarter.
• Over the last five years, Share-based Compensation for EDIT reached as high as $16.6 million in Q3 2024 and fell as low as -$15.9 million in Q4 2024.
• Historically, Share-based Compensation has averaged $2.1 million across 5 years, with a median of $4.7 million in 2023.
• Across the five-year window, Share-based Compensation slumped 311.63% in 2021 and jumped 1158.17% in 2022, its largest moves.
• Year by year, Share-based Compensation stood at -$12.0 million in 2021, then surged by 60.79% to -$4.7 million in 2022, then plunged by 148.53% to -$11.7 million in 2023, then slumped by 36.04% to -$15.9 million in 2024, then soared by 104.81% to $766000.0 in 2025.
• Per Business Quant data, the three most recent Share-based Compensation figures were $766000.0 in Q1 2025, -$15.9 million in Q4 2024, and $16.6 million in Q3 2024.